Hoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy.
Jean Hoffman-Censits, MD, medical oncologist, director, Multidisciplinary Genitourinary Oncology Center, Thomas Jefferson University Hospital, discusses the potential future of the investigational PD-L1 inhibitor atezolizumab. Hoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More